Work

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2523

Authors: Judith Raimbourg, Martin Gutierrez, Antoine Italiano, Shiraj Sen, Afaf Abed, Jermaine Ian George Coward, Muhammad Furqan, Dingzhi Huang, Rongbo Lin, Pu Sun, Zhaoyin Zhu, Rose Huang, Andongfac Florinas, Hua-Xin Gao, Christophe Le Tourneau

Institutions: Institut de Cancérologie de l'Ouest, Hackensack University Medical Center, Institut Bergonié, Linear Clinical Research, Icon (Australia), University of Iowa, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Fujian Provincial Cancer Hospital, BeOne Medicines (Switzerland), Institut Gustave Roussy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162487095

Cites:

Cited by:

Related to: